Gyre Therapeutics (GYRE) Shares Outstanding (2010 - 2026)

Gyre Therapeutics (GYRE) has 17 years of Shares Outstanding data on file, last reported at $91.3 million in Q1 2026.

• Quarterly Shares Outstanding rose 4.22% year-over-year to $91.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $91.3 million (up 4.22% YoY) and the FY2025 annual result came in at $91.3 million, up 5.8% from the prior year.
• Shares Outstanding held at $91.3 million in Q1 2026 per GYRE's latest filing, from $91.3 million in the prior quarter.
• Across five years, Shares Outstanding topped out at $91.3 million in Q1 2026 and bottomed at $31.5 million in Q1 2022.
• The 5-year median for Shares Outstanding is $85.4 million (2024), against an average of $71.8 million.
• The widest annual swing landed in 2022, when Shares Outstanding changed 0.0%; it then surged 102.01% in 2023.
• Tracing GYRE's Shares Outstanding over 5 years: stood at $63.6 million in 2022, then grew by 20.46% to $76.6 million in 2023, then rose by 12.68% to $86.3 million in 2024, then climbed by 5.8% to $91.3 million in 2025, then climbed by 0.03% to $91.3 million in 2026.
• Per Business Quant, the three latest GYRE Shares Outstanding figures stand at $91.3 million (Q1 2026), $91.3 million (Q4 2025), and $90.9 million (Q3 2025).

Peer Comparison